Dyadic®

Reinventing Biologic Vaccine and Drug Development & Production
Biopharmaceuticals C1 Technology Platform Research and Development Partnerships and Licensing Biotherapuetic Manufacturing
Biopharmaceuticals

C1 Technology Platform

Research & Development

Partnering & Licensing

Manufacturing

As the aging population grows there is a critical need to bring biologic vaccines and drugs to market faster, with improved performance, in greater volumes to improve access and reduce costs to patients and the healthcare system. The industrially proven C1 Expression System has the potential to bring novel biologic drugs such as vaccines and antibodies to market faster, in greater volumes and at lower cost to patients and the healthcare system. The C1 technology platform is being used by leading global companies which includes BASF, DuPont and others. Dyadic is seeking partnerships to sub-license, or partner its C1 platform technology in the vaccine, antibody and biosimilar industries. We have industrial scale manufacturing expertise at up to 500,000 liter scale. Commercial products have been produced utilizing the C1 platform technology at industrial scale in 5 countries over 17 years.
Find Out More Find Out More Find Out More Find Out More Find Out More

Watch A Short Video by Dr. Albert Osterhaus

UPCOMING EVENTS

World Health Organization

September 14, 2022 - WHO virtual consultation on novel manufacturing technologies for monoclonal antibody production

Dyadic
Investor Center